GlaxoSmithKline Biologicals v C.P. Pharmaceuticals International C.V. (CFI, 10 August 2026)
| Date | 10 August 2026 |
|---|---|
| Court | CFI |
| Division | The Hague (NL) Local Division |
| Type of action | Infringement Action |
| Case number(s) | UPC_CFI_621/2025 |
| Registry reference | UPC_CFI_621/2025 |
| Parties | GlaxoSmithKline Biologicals SA v. C.P. Pharmaceuticals International C.V., Pfizer Export B.V., Pfizer B.V., Pfizer Manufacturing Belgium N.V.,… |
Official decision (PDF) · UPC registry entry
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
By order of 10 August 2026 (UPC_CFI_621/2025, UPC_CFI_1707/2025 and UPC_CFI_1708/2025), The Hague Local Division deals, in the dispute between GlaxoSmithKline Biologicals SA and companies of the Pfizer and BioNTech groups, with the consequences of EPO decisions on two divisional patents stemming from the same application. EP 4 066 856 having been finally revoked by the Technical Board of Appeal on 20 July 2026, the counterclaim directed at it is disposed of as devoid of purpose. For EP 4 226 941, revoked in opposition on 24 June 2026, the division postpones its decision on the stay request and cancels the oral hearing of 30 September 2026, pending the Board’s written reasons.
Question
Should the division rule at once on a stay request under Rule 295 where the Technical Board of Appeal has revoked a related divisional patent but has not yet issued its reasons?
Decision
As the parties agree that there is no need to adjudicate the counterclaim against EP 4 066 856, the division closes that file and orders GSK, as the unsuccessful party, to bear the costs, the amount to be determined later (paragraph 6), on this point the order refers to the costs of “Moderna”, which is not a party to these proceedings. The revocation of that patent has only partial implications for the infringement action, which also rests on EP 4 226 941 (paragraph 7). The likelihood that the latter’s claims will be held invalid is relevant to the stay, but can only be assessed in the light of the Board’s written reasons (paragraph 8). The parties may file submissions within four weeks of those reasons and reply within three weeks.
Key points for practice
- An EPO decision on a divisional patent may bear on a stay request concerning a patent of the same family. The division prefers to see the reasons rather than rule on the outcome alone.
- The oral hearing on the merits may be postponed pending those reasons, with a timetable for submissions confined to their impact.
Provisions applied
- Rules of Procedure
- Rules 9, 295 and 360
- Case law cited
- No UPC decision, the order refers to the decisions of the EPO Opposition Division of 24 June 2026 and of the Technical Board of Appeal of 20 July 2026.
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Going further
Lexicon: Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.
Dhenne Avocats blog: Pharmaceutical patents and the UPC: is the Court hostile to them?.
Publications by Matthieu Dhenne: The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Parties
- claimantGlaxoSmithKline Biologicals SA16 decisions in the corpusFollow this party
- defendantC.P. Pharmaceuticals International C.V2 decisions in the corpusFollow this party
- defendantPfizer Export B.V.2 decisions in the corpusFollow this party
- defendantPfizer B.V.4 decisions in the corpusFollow this party
- defendantPfizer Manufacturing Belgium N.V.9 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
What the record states
- Nature of the act
- Infringement Action
- Outcome (Dhenne Avocats summary)
- La demande reconventionnelle visant EP 4 066 856, définitivement révoqué par l’OEB, est déclarée sans objet, frais à la charge de GSK. La décision sur le sursis concernant EP 4 226 941 est reportée et l’audience du 30 septembre 2026 annulée.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 4 066 856mentioned in: summary of the decision, Dhenne Avocats analysis Follow this patentEP 4 226 941mentioned in: summary of the decision, Dhenne Avocats analysis Follow this patent
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 4 066 856 | Patent at issue according to the summary or official headnote Also mentioned in 3 other decision(s): GlaxoSmithKline Biologicals v Moderna Netherlands (CFI, 10 August 2026 · GlaxoSmithKline Biologicals v Moderna (CFI, 25 February 2026) · GlaxoSmithKline Biologicals v Moderna Netherlands (CFI, 28 November 20 | not recorded | not recorded | not recorded | Espacenet links not checked mentioned in: summary of the decision, Dhenne Avocats analysis |
EP 4 226 941 | Patent at issue according to the summary or official headnote Also mentioned in 3 other decision(s): GlaxoSmithKline Biologicals v Moderna Netherlands (CFI, 10 August 2026 · GlaxoSmithKline Biologicals v Moderna (CFI, 25 February 2026) · GlaxoSmithKline Biologicals v Moderna Netherlands (CFI, 28 November 20 | not recorded | not recorded | not recorded | Espacenet links not checked mentioned in: summary of the decision, Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.